This regulation grants a remission of anti-dumping duties on certain iodinated contrast media products imported into Canada from the United States, specifically for products exported by Searle Ltd. or Bristol-Myers Squibb Company and imported by Nycomed Amersham Canada Ltd. or Bracco Diagnostics Canada Inc., during a specified period, with the remission amount based on comparisons to reference values and resale prices, and subject to eligibility conditions including timely claims and audit compliance. The remission is calculated using specific methodologies tied to export prices, resale prices, and cost and profit amounts, and is indexed annually to inflation.